title: Mitomycin C-augmented deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma: a three-year prospective study.
abstract: OBJECTIVE
  To investigate the efficacy and safety of mitomycin C (MMC)-augmented deep sclerectomy with implant (DSCI) in primary open-angle glaucoma (POAG) and exfoliation glaucoma (ExG) patients.
  
  
  METHODS
  A total of 68 eyes of 68 patients with POAG and ExG were enrolled consecutively to undergo DSCI with MMC (0.4 mg/ml for 2 min). The intraocular pressure (IOP), number of antiglaucoma medications, neodymium:yttrium-aluminum-garnet (Nd:YAG) laser goniopuncture treatments and complications were compared postoperatively after 36- month follow-up. Surgery was considered as a complete success when IOP was <18 mmHg without antiglaucoma medication.
  
  
  RESULTS
  Preoperatively the mean IOPs were 23 ± 6 mmHg and 25 ± 8 mmHg, and 13 ± 4 mmHg and 11 ± 4 mmHg in the POAG and ExG groups, respectively, at 36 months. At 36 months, 74% and 73% of surgeries were a complete success in the POAG and ExG group, respectively [not significant (NS)]. Two patients (8%) of the POAG group and one of the ExG group (3%) were receiving antiglaucoma medication at 36 months (NS). Nd:YAG laser goniopuncture was performed more often in the ExG group (87%) than in the POAG group (61%, p = 0.024). Postoperatively choroidal detachment occurred in 16% of eyes in the POAG group and in 11% of eyes in the ExG group (NS).
  
  
  CONCLUSIONS
  DSCI with MMC augmentation appears to be as effective in patients with ExG and POAG in lowering IOP to target levels at medium term with few immediate postoperative complications.
authors.affiliation: Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland. minna.ollikainen@fimnet.fi
authors.forename: Minna L
authors.initials: ML
authors.lastname: Ollikainen
authors.forename: Tuomo J
authors.initials: TJ
authors.lastname: Puustjärvi
authors.forename: Petri K
authors.initials: PK
authors.lastname: Rekonen
authors.forename: Hannu M
authors.initials: HM
authors.lastname: Uusitalo
authors.forename: Markku E
authors.initials: ME
authors.lastname: Teräsvirta
mesh_terms: D000368:Aged; D000477:Alkylating Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D017889:Exfoliation Syndrome / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D007431:Intraoperative Complications; D053685:Laser Therapy; D053844:Lasers, Solid-State; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D011183:Postoperative Complications; D011446:Prospective Studies; D012590:Sclera / Q000187:drug effects / Q000601:surgery; D012599:Sclerostomy / Q000379:methods*; D014065:Tonometry, Ocular; D014130:Trabeculectomy
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin